Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Junck

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Neuro-Oncology|January 1, 2017
Leptomeningeal metastases: a RANO proposal for response criteriaMarc Chamberlain, Larry Junck, Dieta Brandsma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survivalDaniel A Hamstra, Craig J Galbán, Charles R Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2016
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation StudyMichelle M Kim, Sandra Camelo-Piragua, Matthew Schipper, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessmentCraig J Galbán, Thomas L Chenevert, Charles R Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2005
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade gliomaDaniel A Hamstra, Thomas L Chenevert, Bradford A Moffat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium studyMonica E Loghin, Michael D Prados, Patrick Wen, et al.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Neuro-Oncology|March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, Kathleen Lamborn, W K A Yung, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Neuro-Oncology|January 1, 2017
Leptomeningeal metastases: a RANO proposal for response criteriaMarc Chamberlain, Larry Junck, Dieta Brandsma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survivalDaniel A Hamstra, Craig J Galbán, Charles R Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2016
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation StudyMichelle M Kim, Sandra Camelo-Piragua, Matthew Schipper, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessmentCraig J Galbán, Thomas L Chenevert, Charles R Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2005
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade gliomaDaniel A Hamstra, Thomas L Chenevert, Bradford A Moffat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium studyMonica E Loghin, Michael D Prados, Patrick Wen, et al.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Neuro-Oncology|March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, Kathleen Lamborn, W K A Yung, et al.
Pageof 9